BCR and chronic myelogenous leukemia, BCR-ABL1 positive: DLI is used to amplify the graft versus leukemia (GvL) effect and has shown particular success in cases of chronic myeloid leukemia (CML) when addressing impending relapse, especially when detected at the cytogenetic (BCR-ABL) or molecular level (2–5).